Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

Curr Treat Options Oncol. 2020 Apr 21;21(4):34. doi: 10.1007/s11864-020-0710-x.


There is increasing awareness that AML is a widely heterogeneous disease, not only based on clinical characteristics and demographics of the patients we treat but also based on the genomics of the disease. Wider accessibility to next-generation DNA sequencing in AML has identified recurrent genetic abnormalities that drive disease biology, define overall prognosis, and predict for response to newly developed target-specific therapies. This knowledge has allowed the field to move away from a "one-size-fits-all" approach in newly diagnosed AML, to a more thoughtful, individualized approachy based on these factors. The first steps in realizing this new approach involve developing systems to efficiently obtain and analyze patient- and disease-related factors prior to starting therapy and having available clinical trials to address each subtype.

Keywords: Acute myeloid leukemia; FLT3; IDH1; IDH2; Secondary AML; TP53.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Clinical Decision-Making
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / therapy*
  • Mutation
  • Precision Medicine* / methods


  • Biomarkers, Tumor